Politician trade (House)

Pfizer (PFE): Rep. Gilbert Ray Cisneros Jr. (CA31) disclosed a partial sale $1K–$15K

Rep. Gilbert Ray Cisneros Jr. (CA31) disclosed a partial sale of Pfizer in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
25 days
Disclosure lag
Traded
Mar 13, 2026
Disclosed
Apr 7, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jun 17, 2025Congress · 1 personMembers of Congress: 2 purchases
  2. Dec 19, 2025CongressDisclosed partial sale of PFE — reported range $1,001 - $15,000
  3. Dec 31, 2025CongressDisclosed sale of PFE — reported range $100,001 - $250,000
  4. Jan 23, 2026Federal contract · $22K obligatedDepartment of Defense awarded Pfizer: $22K obligated to date
  5. Jan 26, 2026Federal contract · $9K obligatedDepartment of Defense awarded Pfizer: $9K obligated to date
  6. Jan 29, 2026Federal contract · $3K obligatedDepartment of Defense awarded Pfizer: $2.8K obligated to date
  7. Feb 3, 2026Company filing · Form 8-K · ResultsReported its results
  8. Feb 9, 2026Government · Federal Register ruleAir Plan Approval; Connecticut; Revised Format for Materials Incorporated by Reference
  9. Feb 10, 2026CongressDisclosed purchase of PFE — reported range $1,001 - $15,000
  10. Feb 18, 2026Federal contract · $8K obligatedDepartment of Defense awarded Pfizer: $8.2K obligated to date
  11. Feb 19, 2026Government · Federal Register noticeGranting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
  12. Feb 24, 2026FDAFDA drug approval: Braftovi
  13. Feb 24, 2026FDAFDA drug approval: Braftovi
  14. Feb 26, 2026Government · Federal Register noticeDetermination of Regulatory Review Period for Purposes of Patent Extension; ORLYNVAH
  15. Mar 6, 2026FDAFDA drug approval: Xeljanz
  16. Mar 6, 2026FDAFDA drug approval: Xeljanz XR
  17. Mar 9, 2026Government · Federal Register noticeAspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications
  18. Mar 13, 2026 · this disclosureCongressDisclosed partial sale of PFE — reported range $1,001 - $15,000

What came next

  1. Mar 27, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  2. Apr 3, 2026Government · Federal Register noticeDetermination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
  3. Apr 8, 2026Federal contract · $15K obligatedDepartment of Defense awarded Pfizer: $15K obligated to date
  4. Apr 23, 2026Federal contract · $2K obligatedDepartment of Defense awarded Pfizer: $2.2K obligated to date
  5. Apr 23, 2026Federal contract · $23K obligatedDepartment of Defense awarded Pfizer: $23K obligated to date
  6. May 1, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  7. May 5, 2026Company filing · Form 8-K · ResultsReported its results
  8. May 13, 2026Federal contract · $25K obligatedDepartment of Defense awarded Pfizer: $25K obligated to date
  9. May 15, 2026Federal contract · $543K obligatedDepartment of Health and Human Services awarded Pfizer: $543K obligated to date
  10. May 20, 2026Federal contract · $2K obligatedDepartment of Defense awarded Pfizer: $2.2K obligated to date
  11. Jun 5, 2026FDAFDA drug approval: Hympavzi
  12. Jun 8, 2026Government · Federal Register noticeDetermination That Protamine Sulfate (Protamine Sulfate) Intravenous; Solution, 50 Milligrams/5 Milliliters, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
  13. Jun 9, 2026InsiderOfficer sold ~$51K of PFE shares in the open market
  14. Jun 18, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On June 16, 2026, Dave Denton notified Pfizer Inc. (the “Company”) that he will step down from his current position as Chief Financial Officer effective August 15, 2026 for a professional opportunity outside of the pharmaceutical industry in consumer goods, and that his departure is not related to the Company’s financial or operating results or to any disagreements with the Company regarding the Company’s financial,…”
  15. Jun 24, 2026FDAFDA drug approval: Ibrance
  16. Jun 24, 2026FDAFDA drug approval: Ibrance
  17. Jul 6, 2026Government · Federal Register noticeEndo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Pfizer

For Pfizer, OQRO holds 1 fund holdings report (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PFE page.

Other recent filings by Rep. Gilbert Ray Cisneros Jr. (CA31)

The full history of Rep. Gilbert Ray Cisneros Jr. (CA31) is on the profile page.

How this filing works

Explore the data

Common questions

Which member of Congress traded Pfizer (PFE) stock, and how much?

Rep. Gilbert Ray Cisneros Jr. (CA31) disclosed a partial sale of Pfizer in the $1K–$15K range. Reported range, not an exact amount.

When did it happen, and when was it made public?

Traded: Mar 13, 2026. Disclosed: Apr 7, 2026. That is 25 days between the two dates.

Why is the amount a range and not an exact figure?

Members of Congress report each trade in a bracket set by law ($1,001 to $15,000, $15,001 to $50,000, and so on), never an exact amount. OQRO keeps the bracket as filed and does not estimate a figure inside it.

Where does this information come from?

From the House Clerk periodic transaction report, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Pfizer recently?

For Pfizer, OQRO holds 1 fund holdings report (13F) and 1 federal contract award dated in the last 90 days. They are listed on the PFE page.

Does this mean PFE stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Pfizer

Everything OQRO holds on this company is on its PFE page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data